Study of Inosine combined with treatment for Esophageal Cancer and its relationship with a biological marker called CD26

Evaluation of CD26 as a potential biomarker and Inosine in combination therapy for Esophageal Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

REBEC

Registry ID

RBR-6m99pxy

Enrollment

Registered

2026-07-19

Start date

2025-04-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal adenocarcinoma

Interventions

This is a randomized, two-arm, open-label interventional clinical study. Approximately 47 patients diagnosed with esophageal adenocarcinoma or esophageal squamous cell carcinoma treated at the Oncolog

Eligibility

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Participants at least 18 years of age on the date of signing the Informed Consent Form; male or female participants with histologically or cytologically confirmed diagnosis of locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma or esophageal adenocarcinoma; participants initiating treatment with an anti-programmed cell death protein 1 or anti-programmed death-ligand 1 agent; Eastern Cooperative Oncology Group performance status of 0 or 1

Exclusion criteria

Exclusion criteria: Absence of tumor tissue in paraffin block for immunohistochemical analysis; inability to collect blood samples for evaluation; history or current evidence of any medical condition, therapy, laboratory abnormality, or other circumstance that may confound the study results or interfere with participation throughout the study period, in a manner that is not in the participant's best interest, according to the assessment of the investigator responsible for treatment

Design outcomes

Primary

Measure	Time frame
To evaluate event-free survival. The outcome will be assessed through clinical and radiological follow-up of participants. An event will be defined as local, regional, or distant radiological recurrence assessed by the investigator, clinical recurrence with histopathological confirmation, or death from any cause. The time elapsed between randomization and the first event during the study follow-up period will be measured.;To evaluate overall survival. The outcome will be assessed through clinical follow-up of participants. The time elapsed between randomization and death from any cause during the study follow-up period will be measured.	—

Measure

Time frame

To evaluate event-free survival. The outcome will be assessed through clinical and radiological follow-up of participants. An event will be defined as local, regional, or distant radiological recurrence assessed by the investigator, clinical recurrence with histopathological confirmation, or death from any cause. The time elapsed between randomization and the first event during the study follow-up period will be measured.;To evaluate overall survival. The outcome will be assessed through clinical follow-up of participants. The time elapsed between randomization and death from any cause during the study follow-up period will be measured.

—

Secondary

Measure	Time frame
No secondary outcomes are expected.	—

Countries

Contacts

Public ContactLaisa Silveira

Hospital Nossa Senhora da Conceição S.A.

laisa.silveira@cipors.com+5551992116705

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Aug 10, 2026